ResMed announced that it has entered into a definitive agreement to acquire Noctrix Health, a medical technology company focused on treating restless legs syndrome (RLS). The acquisition marks a strategic expansion of ResMed’s portfolio into adjacent neurological sleep disorders, reinforcing its mission to improve patient outcomes and quality of life.
Under the terms of the agreement, ResMed will acquire Noctrix Health for approximately $340 million. The transaction is expected to close around June 1, 2026, subject to customary closing conditions.
Noctrix Health is the developer of the FDA-cleared Nidra® device, a non-invasive, drug-free therapy designed to treat RLS, a neurological condition that disrupts sleep and affects an estimated 7% of adults globally. The condition represents one of the most prevalent sleep disorders worldwide, creating a significant opportunity to expand treatment access through established sleep care channels.
“ResMed is uniquely positioned to scale innovative therapies that improve sleep health,” said Mick Farrell, Chairman and CEO of ResMed. “The acquisition of Noctrix Health expands our reach into RLS, the third most prevalent sleep disorder, and aligns with our strategy to address a broader range of sleep-related conditions through connected, patient-centric solutions.”
The addition of Noctrix Health strengthens ResMed’s presence beyond its core obstructive sleep apnea (OSA) business, bringing new capabilities in neurology and wearable therapeutics. The Nidra device is prescribed by sleep physicians and distributed through similar home medical equipment (HME) channels as ResMed’s existing products, enabling immediate commercial synergies.
Noctrix currently generates approximately $24 million in annual revenue and is expected to deliver higher growth and gross margins than ResMed’s traditional business lines. ResMed plans to invest in research and development, as well as commercial expansion, to accelerate adoption of the therapy globally.
“This acquisition represents a natural extension of our ecosystem,” Farrell added. “By leveraging our global scale, digital platforms, and provider relationships, we can bring effective, non-pharmacological treatment options to millions of underserved patients.”
The transaction is expected to be modestly dilutive to ResMed’s near-term earnings, with an anticipated impact of approximately $0.02 per share in the fourth quarter of fiscal year 2026. However, the company expects the deal to contribute to long-term revenue growth and margin expansion.
The acquisition also reflects a broader trend of convergence between sleep medicine, neurology, and digital health. By integrating Noctrix’s technology into its portfolio, ResMed continues to advance its vision of a comprehensive sleep health platform that addresses multiple conditions affecting sleep quality.
With a strong balance sheet and continued investment in innovation, ResMed remains focused on expanding its global leadership in sleep health, improving patient adherence, and delivering better outcomes across a growing range of sleep-related disorders.
Source SleepWorld Magazine
